Strategic Acquisition Acceleron Pharma was acquired by Merck for $11.5 billion, positioning the company under a new entity with vast resources and potentially opening avenues for collaborative sales strategies leveraging Merck's existing network and market presence.
Key Drug Launch The recent launch of the drug Reblozyl by Acceleron Pharma in the first-line setting for MDS presents a significant sales opportunity. With promising sales figures post-launch, this blockbuster therapy could be leveraged to capture a larger market share and drive revenue growth.
Partnership Potential Acceleron Pharma's partnership with Merck indicates a shared focus on innovation and market expansion. This collaboration presents an opportunity for joint sales efforts, combined expertise, and potentially cross-selling opportunities to reach a wider customer base.
Financial Strength With a revenue between $50-$100 million and funding of $493 million, Acceleron Pharma demonstrates financial stability and capacity for further investments in sales and marketing strategies to capitalize on market opportunities and drive business growth.
Competitive Dynamics The acquisitions and partnerships involving Acceleron Pharma highlight a dynamic competitive landscape. Identifying and capitalizing on gaps left by competitors, especially after failed acquisition attempts by other companies, can present strategic sales openings for Acceleron to seize market share.
587
$50M$100M
6.1K$1B
966$100M$1B
5K$100M$1B
3.8K$100M$1B
1.4K$1B
334$50M$100M
1.5K$100M$1B
585$50M$100MAcceleron Pharma uses 8 technology products and services including SiteCatalyst, GitHub, SAP, and more. Explore Acceleron Pharma's tech stack below.
| Acceleron Pharma Email Formats | Percentage |
| FLast@acceleronpharma.com | 92% |
| First.Last@acceleronpharma.com | 5% |
| Last@acceleronpharma.com | 2% |
| FMiddleLast@acceleronpharma.com | 1% |
Biotechnology ResearchMassachusetts, United States201-500 Employees
Effective 11/22/21, Acceleron Pharma Inc. is now a wholly-owned subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada) http://merck.com
Company Overview
Media & News
Funding & FinancialsAcceleron Pharma has raised a total of $493M of funding over 15 rounds. Their latest funding round was raised on Jun 30, 2020 in the amount of $493M.
Acceleron Pharma's revenue is in the range of $50M$100M
Funding & FinancialsAcceleron Pharma has raised a total of $493M of funding over 15 rounds. Their latest funding round was raised on Jun 30, 2020 in the amount of $493M.
Acceleron Pharma's revenue is in the range of $50M$100M
1-888-653-2347 
support@leadiq.com